Pravin Deshmukh, MD
Internal Medicine · Richmond, VANPI 1073511200
Payments from drug & device makers
Across 158 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$506
- AbbVie$449
- Amgen$222
- Lilly USA, LLC$155
- Biohaven Pharmaceutical Holding Company Ltd.$110
- Abbott$106
- plus $958 from 28 others
What the payments were for
- Food & beverage$2,506100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $506 |
| AbbVie | 27 | $449 |
| Amgen | 15 | $222 |
| Lilly USA, LLC | 10 | $155 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $110 |
| Abbott | 6 | $106 |
| Boston Scientific | 5 | $102 |
| Pfizer | 5 | $97 |
| Novartis | 4 | $73 |
| Amarin Pharma, Inc. | 3 | $67 |
| Sanofi-aventis U.S. LLC | 5 | $67 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| GSK | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Bayer | 2 | $38 |
| Johnson & Johnson | 3 | $36 |
| Eisai Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Atricure, Inc. | 1 | $27 |
| AstraZeneca | 2 | $26 |
| Medtronic | 2 | $25 |
| BETA Bionics, Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Metuchen Pharmaceuticals | 1 | $11 |
How this compares
$2,506 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 135 | $146,069 |
| FarxigaDapagliflozin Propanediol | 50 | $65,518 |
| JardianceEmpagliflozin | 60 | $64,491 |
| EliquisApixaban | 51 | $60,783 |
| JanuviaSitagliptin Phosphate | 55 | $60,239 |
| OzempicSemaglutide | 40 | $54,957 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $48,583 |
| XareltoRivaroxaban | 31 | $29,997 |
| LinzessLinaclotide | 25 | $29,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $26,182 |
| RybelsusSemaglutide | 15 | $24,587 |
| Darunavir | 12 | $21,429 |
| IsentressRaltegravir Potassium | 11 | $20,027 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $17,184 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $16,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $155 | $146,069135 claims |
| MerckJanuvia, Janumet, Isentress | $15 | $128,850103 claims |
| AstraZenecaFarxiga, Symbicort | $26 | $81,86084 claims |
| Novo NordiskOzempic, Rybelsus | $506 | $79,54455 claims |
| PfizerEliquis | $97 | $60,78351 claims |
| Johnson & JohnsonXarelto | $36 | $29,99731 claims |
| AbbVieLinzess | $449 | $29,42025 claims |
| GSKTrelegy Ellipta | $40 | $26,18230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Richmond
- Leroy VaughanRichmond$20.8M
- Andrew PoklepovicRichmond$4.6M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.